Contribution to the Personalized Management of the Nosocomial Infections: A New Paradigm Regarding the Influence of the Community Microbial Environment on the Incidence of the Healthcare-Associated Infections (HAI) in Emergency Hospital Surgical Departments
Abstract
:1. Introduction
2. Working Hypothesis
- ➢
- The preventive component, in this case, is represented by:
- ○
- The prevention of HAI.
- ○
- The prevention of the spread and maximal limitation of bacterial multiresistance in the hospital wards.
- ○
- The prevention of antibiotic resistance.
- ➢
- The predictive component is represented by:
- ○
- Knowing the germs usually found in each ward area (bacteriological map), which leads to the possibility of establishing dedicated antibiotic treatment (based on the statistical bacteriologic results of the ward, which are significantly higher than the initial three-day period of “broad spectrum” treatment);
- ○
- Ensuring the supply of the ward with antibiotics from the antibiotic resistance spectrum specific to the most frequent germs found in patients in the ward.
- ○
- Anticipating the type of infectious evolution from wound infections.
- ➢
- The personalized component is characterized by:
- ○
- Individual analysis of the local bacteriological status from the first moment of each patient’s hospitalization.
- ○
- Establishing treatment depending on the antibiotic sensitivity test results.
- ○
- Ensuring the specific environmental conditions that limit cross-infection with multiresistant germs.
3. Materials and Methods
- Analysis of the pathogenic microorganisms at the level of patient wounds from the moment of admission into the hospital (after the interaction between the macroorganisms and microorganisms in the community environment, after the occurrence of the pathological gateway);
- Analysis of the pathogenic multiresistant microorganisms at the level of wounds from admission, thus entering the hospital environment.
- Identification of all categories of pathogenic microorganisms frequently existing in the studied in-hospital environment.
- Identification of pathogenic species entering the community along with the discharge of the studied subjects.
4. Results
- The demographic data were the following: 76.77% men and 48.42% women. The average age was 47.76 (min. 12 max. 95).
DIAGNOSTIC | CASE NO. | PERCENTAGE DISTRIBUTION |
---|---|---|
Multiple/mixed injuries | 719 | 73.90% |
Burns | 133 | 13.67% |
Bone, joint and soft tissue infections | 121 | 12.44% |
973 | 100.00% |
LOCATION OF INJURY | TYPE OF INJURY | CASE NO. | PERCENTAGE |
---|---|---|---|
DISTRIBUTION | |||
Musculotendinous and neurovascular | 602 | 61.87% | |
Limbs | |||
Bone and joint | 42 | 4.32% | |
Other | 75 | 7.71% | |
73.90% |
- 3.
- The average hospitalization period was eight and twelve days (min. 1, max. 101).
- 4.
- The highest incidence of microorganisms found at the time of patients’ hospitalization was noticed in the case of complex (musculotendinous and neurovascular) traumas, followed by traumatic amputations, and infections of soft tissues, bones, joints, and burns (Table 3).
Gram Stain | Musculo Tendinous and Neuro Vascular | Traumatic Amputation | Bone, Joint and Soft Tissue Infections | Burns | Crush Injuries | Other Injuries | Bone and Joint Trauma | Total | ||
---|---|---|---|---|---|---|---|---|---|---|
CoNS | + | 113 | 61 | 42 | 47 | 37 | 29 | 15 | 344 | |
S. aureus (MSSA) | + | 50 | 16 | 31 | 26 | 15 | 8 | 8 | 154 | |
Staphylococcus spp. | + | 47 | 28 | 7 | 13 | 17 | 15 | 5 | 132 | |
Klebsiella spp. | − | 26 | 9 | 15 | 6 | 10 | 8 | 5 | 79 | |
Enterococcus spp. | + | 27 | 11 | 7 | 14 | 9 | 9 | 1 | 78 | |
P. aeruginosa | − | 23 | 9 | 4 | 7 | 9 | 5 | 1 | 58 | |
E. coli | − | 13 | 4 | 4 | 6 | 5 | 5 | 2 | 39 | |
Acinetobacter spp. | − | 12 | 1 | 6 | 5 | 5 | 5 | 4 | 38 | |
S. aureus (MRSA) | + | 9 | 2 | 7 | 9 | 3 | 3 | 4 | 37 | |
Proteus spp. | − | 6 | 5 | 9 | 4 | 0 | 6 | 0 | 30 | |
Streptococcus spp. | + | 7 | 2 | 8 | 1 | 2 | 2 | 1 | 23 | |
Klebsiella spp. (ESBL) | − | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 5 | |
Enterobacter spp. | + | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 4 | |
Enterococcus spp. (HLAR) | + | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 3 | |
E. coli ( ESBL) | − | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 3 | |
Serratia spp. | − | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | |
Serratia spp. (ESBL) | − | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |
Candida spp. | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||
338 | 151 | 145 | 141 | 113 | 95 | 48 | 1031 | Total | ||
32.78% | 14.65% | 14.06% | 13.68% | 10.96% | 9.21% | 4.66% | Percentage distribution |
- 5.
- Out of the total number of 973 samples collected at hospitalization, 702 (72.15%) were positive (monobacterial and multibacterial), with 1030 bacterial strains (of which there were 771 Gram-positive cocci at 74.85% and 259 Gram-negative bacilli at 25.15%) and one fungal strain isolated. Of the isolated Gram-positive bacteria, the most frequent were Staphylococcus species (86.51% of Gram-positive), representing 64.7% of the total isolated strains, while Klebsiella was 8.16% and Pseudomonas aeruginosa species was 5.63%, mainly emphasized in the case of Gram-negative bacilli (Table 4).
Percentage Distribution | |||
---|---|---|---|
STAPHYLOCOCCUS SPP. | |||
GRAM + | 771 | 667 | 64.76% |
KLEBSIELLA SPP. | |||
84 | 8.16% | ||
GRAM − | 259 | ||
P. AERUGINOSA | 5.63% | ||
58 | |||
Total strains | 1030 |
- 6.
- In total, seventeen bacterial species and one fungal species were identified at the start of hospitalization, which is an important number of microorganisms. Their distribution is presented in Table 5.
Microorganisms | No. | Percentage Distribution |
---|---|---|
CoNS | 344 | 33.37% |
S. aureus (MSSA) | 154 | 14.94% |
Staphylococcus spp. | 132 | 12.80% |
Klebsiella spp. | 79 | 7.66% |
Enterococcus spp. | 78 | 7.57% |
P. aeruginosa | 58 | 5.63% |
S. aureus (MRSA) | 37 | 3.59% |
E. coli | 39 | 3.78% |
Acinetobacter spp. | 38 | 3.69% |
Proteus spp. | 30 | 2.91% |
Streptococcus spp. | 23 | 2.23% |
Klebsiella spp. (ESBL) | 5 | 0.48% |
Enterobacter spp. | 4 | 0.39% |
Enterococcus spp. (HLAR) | 3 | 0.29% |
E. coli (ESBL) | 3 | 0.29% |
Serratia spp. | 2 | 0.19% |
Serratia spp. (ESBL) | 1 | 0.10% |
Candida spp. | 1 | 0.10% |
1031 | 100.00% |
- 7.
- We aimed to identify the microbial associations at the start of the hospitalization of patients. The analysis of the bacteriological results revealed that, of the 973 samples collected, 472 were mono-microbial (48.50%), 230 polymicrobial (23.63%), and the remaining 271 were negative samples (27.85%). The microbial associations involved: 159 cases with two germs, 50 cases with three germs, 17 cases with four germs, three cases with five germs, and one case with seven germs.
- 8.
- Although the results of the microbial associations for hospitalized patients seem “attractive” from a scientific point of view, we considered that the analysis of some types of the multiresistant germs identified was important. Of the total multiresistant species isolated, 49 species drew attention by their higher possibility of infection evolution, out of which S. aureus strains (MRSA) at 3.59% were the most frequent, followed by the strains producing extended-spectrum beta-lactamases: Klebsiella spp. at 0.48%, E. coli at 0.29%, Serratia at 0.10%, and Enterococcus spp. (HLAR) at 0.29%. The antibiotic resistance of these strains is presented in Table 9 and Table 10, according to the criterion of decreasing multiresistance. The existence of strains resistant to all the tested antibiotics was noticed for S. aureus (MRSA), except for Chloramphenicol, and 11 strains were characterized by a common resistance pattern to Penicillin, Oxacillin, Erythromycin, and Clindamycin, but they were sensitive to the other tested antibiotics. Identical resistance patterns were not identified with respect to the Klebsiella, E. coli, and Serratia species.
- 9.
- To obtain a more specific image of the bacteriological conglomerate in the studied patients, their bacteriological status was analyzed during hospitalization, including the hospitalization situation (Table 11). The data from Table 11, column 2 (intermediate bacteriological examination) and column 3 (final bacteriological examination) represent the new microorganisms compared to the previous bacteriological examinations.
- (a)
- Intermediate bacteriological examination: 157 positive samples (22 initially negative, 91 samples with different germs, 44 samples with the same germs) and 59 negative samples (18 initially negative, 41 initially positive). Out of the newly emphasized microorganisms, only two species different from the community ones were isolated, namely: one Proteus spp. (ESBL) strain and one Chryseobacterium indologenes strain.
- (b)
- Final bacteriological examination: 157 positive cultures (19 initially negative, 69 samples with different germs, 69 samples with the same germs) and 112 negative cultures (37 initially negative, 75 initially positive).
5. Discussion
6. Conclusions
- Wounds that occurred due to trauma, or older infected wounds, are frequently contaminated at admission to the hospital with bacteria coming from the adjacent integument or the external environment (lately even multiresistant bacteria).
- The most frequently isolated microorganisms from the wounds at admission were Coagulase-negative Staphylococci, S. aureus, Staphylococcus spp., Klebsiella spp., Enterococcus spp., and P. aeruginosa.
- Among the multiresistant bacteria isolated at admission, 4.75% were identified: S. aureus (MRSA), Enterococcus spp. (HLAR), and strains producing extended-spectrum beta-lactamases: Klebsiella spp., E. coli, and Serratia spp.
- The most frequent bacterial associations encountered in multimicrobial cultures were CoNS-Enterococcus spp., CoNS-S. aureus, CoNS-Klebsiella spp., and other combinations of the four mentioned above.
- Microorganisms circulating in the Plastic Surgery ward upon the hospitalization of patients with septic potential pathology are not only subject to the multiresistance phenomenon, but they are also a part of it; thus, understanding the antibiotic resistance spectrum can lead to stopping the administration of the usual antibiotics as empirical therapy (inefficient in these conditions, and even possibly responsible for amplifying the multiresistance phenomenon).
- The presence of multiresistant community strains that were isolated from wounds at the time of hospitalization requires the administration of antimicrobial agents based on the antibiotic sensitivity test.
- The reduction in the microbial resistance to antibiotics requires the consolidation of an epidemiological supervision system of antibiotic resistance for each ward and medical institution.
- A concerning phenomenon resulting from the study was the emphasis of multiresistant microorganisms prior to admission that could infect or contaminate the patients within the medical system.
- In the case of pathogenic microorganisms (especially multiresistant ones), the community environment has a larger influence on the medical environment, different to several years ago, when it was unanimously accepted that HAI “altered” the bacteriological configuration of the extra-hospital environment. In this context, the hospital has changed in the present from the aggressor environment to a microbiologically aggressed environment. Despite this aggression, the hospital can and must be an entity that filters and annihilates the phenomenon of microorganism re-entrance to the extra-hospital environment by establishing and monitoring well-documented therapeutic protocols.
- The results of this study highlight the necessity of a modern approach to HAI management, which, alongside the preventive component, must also include the predictive and personalized ones.
- The bacteriological status of the patients at admission will not only predict the type of wound infection, but will also be able to ensure their therapeutic management by providing a constant supply with specific antibiotics for the most frequent germs found in each local surgical ward, and establishing adapted protocols and strategies for dealing with the increasing MDR (multiple drug resistance)/XDR (extreme drug resistance) global threat.
- We strongly consider that the management of any hospitalized surgical trauma case at the present time should include, systematically, the new “personalized” component in order to achieve the best treatment, with particular clinical decisions based on the individual characteristics of each patient.
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Baldwin, A.J.; Jackowski, A.; Jamal, A.; Vaz, J.; Rodrigues, J.N.; Tyler, M.; Murray, A.; Wormald, J.C.R. Risk of surgical site infection in hand trauma, and the impact of the SARS-CoV-2 pandemic: A cohort study. J. Plast. Reconstr. Aesthet. Surg. 2021, 74, 3080–3086. [Google Scholar] [CrossRef] [PubMed]
- Australian Wound Management Association. Bacterial Impact on Wound Healing: From Contamination to Infection; Australian Wound Management Association: Watson, Australia.
- European Wound Management Association (EWMA). Position Document: Identifying Criteria for Wound Infection; European Wound Management Association: London, UK, 2005. [Google Scholar]
- Bowler, P.G.; Duerden, B.I.; Armstrong, D.G. Wound Microbiology and Associated Approaches to Wound Management. Clin. Microbiol. Rev. 2001, 14, 244–269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Centers for Disease Control and Prevention (CDC). ANTIBIOTIC RESISTANCE THREATS in the United States; Centers for Disease Control and Prevention (CDC): Atlanta, GA, USA, 2013. [Google Scholar]
- World Health Organization. Overview of the IPC Situation Worldwide: Highlights of Achievements and Gaps; WHO: Geneva, Switzerland, 2022. [Google Scholar]
- Wysocki, A.B. Evaluating and managing open skin wounds: Colonization versus infection. AACN Clin. Issues. 2002, 13, 382–397. [Google Scholar] [CrossRef] [PubMed]
- Soman, R. Colonisation versus Infection. Med. Update 2008, 18, 330–333. [Google Scholar]
- Editorial board of ClinicalMedicine. Antimicrobial resistance: A top ten global public health threat. EClinicalMedicine 2021, 41, 101221. [Google Scholar] [CrossRef] [PubMed]
- Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance. Lancet 2022, 399, 629–655. [Google Scholar]
- Collier, M. Recognition and management of wound infections. World Wide Wounds 2004, 7, 8–14. [Google Scholar]
- Flanagan, M. Wound Healing and Skin Integrity: Principles and Practice; John Wiley & Sons: Hoboken, NJ, USA, 2013. [Google Scholar]
- World Health Organization. WHO Guidelines for Safe Surgery 2009: Safe Surgery Saves Lives; WHO: Geneva, Switzerland, 2009. [Google Scholar]
- Cutting, K.F.; White, R.J.; Mahoney, P.; Harding, K.G. Clinical Identification of Wound Infection: A Delphi Approach. In Position Document: Identifying Criteria for Wound Infection; EWMA, Ed.; European Wound Management Association (EWMA): London, UK, 2005. [Google Scholar]
- Von Eiff, C.; Proctor, R.A.; Peters, G. Coagulase-negative staphylococci; Pathogens have major role in nosocomial infections. Postgrad Med. 2001, 110, 63–64. [Google Scholar] [CrossRef] [Green Version]
- Piette, A.; Verschraegen, G. Role of coagulase-negative staphylococci in human disease. Vet. Microbiol. 2009, 134, 45–54. [Google Scholar] [CrossRef] [Green Version]
- Popescu, G.A.; Codita, I.; Szekely, E.; Serban, R.; Ruja, G.; Tălăpan, D. Ghid privind Enterobacteriaceae producătoare de carbapenemaze: Diagnosticul, prevenirea transmiterii interumane și tratamentul infecțiilor produse. Available online: https://smcampulung.ro/interes_public/medici/GHID_carbapenemaze_23.09.2015.pdf (accessed on 6 November 2022).
- Wilson, A.P.R.; Livermore, D.M.; Otter, J.A.; Warren, R.E.; Jenks, P.; Enoch, D.A.; Newsholme, W.; Oppenheim, B.; Leanord, A.; McNulty, C.; et al. Prevention and control of multi-drug-resistant Gram-negative bacteria: Recommendations from a Joint Working Party. J. Hosp. Infection 2016, 92, S1–S44. [Google Scholar] [CrossRef] [Green Version]
- Abrams, R.A.; Botte, J.M. Hand Infections: Treatment Recommendations for Specific Types. J. Am. Acad. Orthop. Surg. 1996, 4, 219–230. [Google Scholar] [CrossRef] [Green Version]
- Greyling, J.F.; Visser, E.; Elliot, E. Bacteriology and epidemiology of hand infections. Orthop. J. 2012, 11, 1. [Google Scholar]
- Clarck, C.D. Common Acute Hand Infections. Am. Fam. Physician Vol. 2003, 68, 11. [Google Scholar]
- Mohammed, A.; Seid, M.E.; Gebrecherkos, T.; Tiruneh, M.; Moges, F. Bacterial Isolates and Their Antimicrobial Susceptibility Patterns of Wound Infections among Inpatients and Outpatients Attending the University of Gondar Referral Hospital, Northwest Ethiopia. Int. J. Microbiol. 2017, 2017, 3829. [Google Scholar] [CrossRef] [Green Version]
- Mythri, B.A.; Patil, A.P.; Arati, K.; Sharon, V.A. Aerobic Bacteriological Profile from wound site Infections in Road Traffic Accident (RTA) Patients. Indian J. Microbiol. Res. 2016, 3, 37–39. [Google Scholar] [CrossRef]
- NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE SYSTEM. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004. Am. J. infect. Control 2004, 32, 470–485. [Google Scholar] [CrossRef]
- EUROSURVEILLANCE EDITORIAL TEAM. ECDC publishes 2014 surveillance data on antimicrobial resistance and antimicrobial consumption in Europe. Eurosurveillance 2015, 20, 30068. [Google Scholar]
- World Health Organization. Global Annual Analysis “Clean Hands”; WHO: Geneva, Switzerland, 2015. [Google Scholar]
- Popescu, G.A.; Codita, I.; Szekely, E.; Serban, R.; Ruja, G.; Tălăpan, D. Diagnosticul, profilaxia și tratamentul infecțiilor determinate de Staphylococcus aureus meticilinorezistent (MRSA). 2016, 1–27. Available online: https://www.cnscbt.ro/index.php/ghiduri-si-protocoale/519-diagnosticul-profilaxia-si-tratamentul-infectiilor-determinate-de-staphylococcus-aureus-meticilinorezistent-mrsa/file (accessed on 6 November 2022).
- Islam, M.S.; Yusuf, M.A.; Chowdhury, M.; Hossain, M.A. ESBL producing Gram Negative Aerobic Bacteria Isolated from Burn Wound Infection with Their Antibiogram in Dhaka. J. Sci. Found. 2012, 10, 2. [Google Scholar] [CrossRef]
- Treglia, M.; Pallocci, M.; Passalacqua, P.; Sabatelli, G.; De Luca, L.; Zanovello, C.; Messineo, A.; Quintavalle, G.; Cisterna, A.M.; Marsella, L.T. Medico-Legal Aspects of Hospital-Acquired Infections: 5-Years of Judgements of the Civil Court of Rome. Healthcare 2022, 18, 1336. [Google Scholar] [CrossRef]
- Hassan, M.; Tuckman, H.P.; Patrick, R.P.; Kountz, D.S.; Kohn, J.L. Cost of Hospital-Acquired Infection. Hospital Topics 2010, 88, 82–89. [Google Scholar] [CrossRef]
- Wenzel, R.P. The economics of nosocomial infections. J. Hosp. Infect. 1995, 31, 79–87. [Google Scholar] [CrossRef] [PubMed]
MICROORGANISM | CASE NO. |
---|---|
CoNS-Enterococcus spp. | 34 |
CoNS-S. aureus (MSSA) | 20 |
CoNS-Klebsiella spp. | 20 |
Klebsiella spp.-Acinetobacter spp. | 19 |
CoNS-P. aeruginosa | 18 |
S. aureus (MSSA)-Klebsiella spp. | 18 |
Klebsiella spp.-Enterococcus spp. | 17 |
S. aureus (MSSA)-Enterococcus spp. | 16 |
CoNS-E. coli | 15 |
CoNS-Acinetobacter spp. | 12 |
Staphylococcus spp.-Enterococcus spp. | 12 |
Klebsiella spp.-Proteus spp. | 12 |
CoNS-Proteus spp. | 11 |
CoNS-Staphylococcus spp. | 10 |
Klebsiella spp.-P. aeruginosa | 10 |
Proteus spp.-E. coli | 10 |
MICROORGANISM | CASE NO. |
---|---|
S. aureus (MSSA)-Klebsiella spp.-Enterococcus spp. | 7 |
CoNS-Klebsiella spp.-Acinetobacter spp. | 5 |
Klebsiella spp.-Acinetobacter spp.-E. Coli | 5 |
CoNS-S. aureus (MSSA)- Enterococcus spp. | 4 |
CoNS-Klebsiella spp.-Proteus spp. | 4 |
CoNS-Klebsiella spp.-E. Coli | 4 |
CoNS-Proteus spp.-Enterococcus spp. | 4 |
CoNS-Enterococcus spp.-P. Aeruginosa | 4 |
Klebsiella spp.-Acinetobacter spp.-P. Aeruginosa | 4 |
Klebsiella spp.-Acinetobacter spp.-Proteus spp. | 4 |
Klebsiella spp.-Proteus spp.-E. coli | 4 |
CoNS-Klebsiella spp.-Enterococcus spp. | 3 |
CoNS-Enterococcus spp.-E. Coli | 3 |
CoNS-P. Aeruginosa-E. Coli | 3 |
S. aureus (MSSA)-Klebsiella spp.-Acinetobacter spp. | 3 |
Staphylococcus spp.-Klebsiella spp.-Enterococcus spp. | 3 |
Klebsiella spp.-Enterococcus spp.-E. Coli | 3 |
Klebsiella spp.-Enterococcus spp.-P. Aeruginosa | 3 |
Klebsiella spp.-P. Aeruginosa-E. Coli | 3 |
MICROORGANISM (a) | Case no. |
CoNS-Proteus spp.- Enterococcus spp.- E. Coli | 2 |
CoNS-Klebsiella spp.- Acinetobacter spp.- Proteus spp. | 2 |
CoNS-Klebsiella spp.- P. Aeruginosa-E. Coli | 2 |
S. Aureus (MSSA)-Klebsiella spp.- Entercoccus spp.- P. aeruginosa | 2 |
MICROORGANISM (b) | Case no. |
S. Aureus (MSSA)-Klebsiella spp.- Acinetobacter spp.- Enterococcus spp.- P. Aeruginosa-E. Coli-Streptococcus spp. | 1 |
Penicillin | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oxacillin | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
Erythromycin | R | R | R | R | R | R | R | R | R | R | R | R | R | R | S | S | S | S | S |
Clindamycin | R | R | R | R | R | R | R | R | R | R | R | R | R | R | S | S | S | S | S |
Amikacin | R | R | S | S | S | - | S | S | S | S | - | S | S | S | - | - | S | S | S |
Ciprofloxacin | R | R | R | S | R | I | - | - | S | S | S | S | S | S | S | S | S | S | S |
Gentamicin | R | R | R | R | S | S | S | S | S | S | S | - | S | S | S | S | S | S | S |
Levofloxacin | R | R | - | - | - | - | S | S | - | - | - | S | S | S | - | - | S | - | S |
Chloramphenicol | S | S | S | S | S | S | R | S | S | S | S | S | S | S | R | S | S | S | S |
Trimethoprim/sulfamethoxazole | - | - | R | S | S | S | S | S | S | S | S | S | S | S | S | S | - | S | S |
Rifampicin | R | R | S | S | S | S | S | S | S | - | S | S | - | S | S | S | S | S | S |
Linezolid | R | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
Teicoplanin | R | S | S | S | S | S | S | S | S | S | S | S | S | S | S | - | S | S | S |
1 * | 1 * | 1 * | 1 * | 1 * | 1 * | 1 * | 1 * | 11 * | 1 * | 5 * | 1 * | 1 * | 1 * | 1 * | 1 * | 2 * | 4 * | 1 * |
ESBL | HLAR | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Klebsiella spp. | Enterococcus spp. | |||||||||||||||||
E. coli | Serratia spp. | |||||||||||||||||
Ampicillin | R | R | R | R | R | R | R | R | - | S | S | S | ||||||
Amoxicillin/ | S | R | I | R | R | S | I | S | - | - | - | - | ||||||
clavulanic acid | ||||||||||||||||||
Amikacin | S | S | S | S | S | R | S | S | - | - | - | - | ||||||
Ceftazidime | R | R | I | I | S | R | R | R | - | - | - | - | ||||||
Ciprofloxacin | R | S | S | S | S | S | S | S | S | R | R | R | ||||||
Ceftriaxone | R | R | R | S | S | R | R | R | - | - | - | - | ||||||
Chloramphenicol | R | S | R | S | S | S | S | S | S | S | R | R | ||||||
Clindamycin | - | - | - | - | - | - | - | - | S | - | - | - | ||||||
Erythromycin | - | - | - | - | - | - | - | - | S | R | R | R | ||||||
Imipenem | S | S | S | S | S | S | S | S | - | - | - | - | ||||||
Levofloxacin | - | S | - | S | S | - | - | - | S | R | R | R | ||||||
Linezolid | - | - | - | - | - | - | - | - | S | S | S | S | ||||||
Meropenem | - | S | - | S | S | - | - | - | - | - | - | - | ||||||
Oxacillin | - | - | - | - | - | - | - | - | S | - | - | - | ||||||
Penicillin | - | - | - | - | - | - | - | - | R | S | S | S | ||||||
Rifampicin | - | - | - | - | - | - | - | - | - | R | I | S | ||||||
Teicoplanin | - | - | - | - | - | - | - | - | S | S | S | S | ||||||
Trimethoprim/sulfamethoxazole | S | S | S | S | S | - | R | - | - | - | - | - | ||||||
Vancomicin | - | - | - | - | - | - | - | - | - | S | S | S |
Admission Sample | Intermediary Sample | Final Sample | |
---|---|---|---|
CoNS | 344 | 43 | 30 |
S. aureus (MRSA) | 41 | 14 | 13 |
S. aureus (MSSA) | 150 | 17 | 7 |
Staphylococcus spp. | 132 | 16 | 14 |
Klebsiella spp. | 79 | 9 | 4 |
Klebsiella spp. (ESBL) | 5 | 3 | 1 |
Acinetobacter spp. | 38 | 7 | 9 |
Proteus spp. | 30 | 5 | 2 |
Enterococcus spp. | 78 | 21 | 7 |
Enterococcus spp. (HLAR) | 3 | 6 | 3 |
Enterobacter spp. | 4 | 2 | 1 |
Serratia spp. | 2 | 1 | 1 |
Serratia spp. (ESBL) | 1 | 0 | 0 |
P. aeruginosa | 58 | 18 | 13 |
E. coli | 39 | 9 | 3 |
E. coli (ESBL) | 3 | 2 | 1 |
Streptococcus spp. | 23 | 4 | 3 |
Candida spp. | 1 | 3 | 2 |
Proteus spp. (ESBL) | 0 | 1 | 0 |
Chryseobacterium indologenes | 0 | 1 | 0 |
1031 | 182 | 114 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mateescu, M.-C.; Grigorescu, S.; Socea, B.; Bloanca, V.; Grigorescu, O.-D. Contribution to the Personalized Management of the Nosocomial Infections: A New Paradigm Regarding the Influence of the Community Microbial Environment on the Incidence of the Healthcare-Associated Infections (HAI) in Emergency Hospital Surgical Departments. J. Pers. Med. 2023, 13, 210. https://doi.org/10.3390/jpm13020210
Mateescu M-C, Grigorescu S, Socea B, Bloanca V, Grigorescu O-D. Contribution to the Personalized Management of the Nosocomial Infections: A New Paradigm Regarding the Influence of the Community Microbial Environment on the Incidence of the Healthcare-Associated Infections (HAI) in Emergency Hospital Surgical Departments. Journal of Personalized Medicine. 2023; 13(2):210. https://doi.org/10.3390/jpm13020210
Chicago/Turabian StyleMateescu, Maria-Cristina, Simona Grigorescu, Bogdan Socea, Vlad Bloanca, and Ovidiu-Dan Grigorescu. 2023. "Contribution to the Personalized Management of the Nosocomial Infections: A New Paradigm Regarding the Influence of the Community Microbial Environment on the Incidence of the Healthcare-Associated Infections (HAI) in Emergency Hospital Surgical Departments" Journal of Personalized Medicine 13, no. 2: 210. https://doi.org/10.3390/jpm13020210
APA StyleMateescu, M.-C., Grigorescu, S., Socea, B., Bloanca, V., & Grigorescu, O.-D. (2023). Contribution to the Personalized Management of the Nosocomial Infections: A New Paradigm Regarding the Influence of the Community Microbial Environment on the Incidence of the Healthcare-Associated Infections (HAI) in Emergency Hospital Surgical Departments. Journal of Personalized Medicine, 13(2), 210. https://doi.org/10.3390/jpm13020210